Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yan Xia Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9777-8836; OpenAlex author ID A5009940394. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2017: 3 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 3 papers · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. Development and Validation of the Predictive and Prognostic ChemoResist Signature in Resected Pancreatic Ductal Adenocarcinoma: Multicohort Study. Last author DOI 10.1097/sla.0000000000006610↗
  2. Corrections to: “The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super‐enhancer activity and the PI3K/AKT/mTOR signall… Last author DOI 10.1002/ctm2.70158↗
  3. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic… Last author DOI 10.1002/ctm2.1500↗
  4. Gene signature developed for predicting early relapse and survival in early-stage pancreatic cancer. Last author DOI 10.1093/bjsopen/zrad031↗
  5. Pancreatic cancer incidence and mortality trends in urban Shanghai, China from 1973 to 2017: a joinpoint regression and age-period-cohort analysis. Co-author DOI 10.3389/fonc.2023.1113301↗
  6. S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study. Co-author DOI 10.3389/fonc.2022.865404↗
  7. UPLC‑MS/MS‑based metabolomic characterization and comparison of pancreatic adenocarcinoma tissues using formalin‑fixed, paraffin‑embedded and optimal cutting t… Co-author DOI 10.3892/ijo.2019.4898↗
  8. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  9. Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarc… Co-author DOI 10.1038/s41598-017-00859-5↗
  10. Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemother… First author DOI 10.18632/oncotarget.16980↗
  11. Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Co-author DOI 10.18632/oncotarget.21359↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guanghai Dai · 7 shared papers, 2017–2025 · strength 1.21
  2. Lei Huang · 5 shared papers, 2022–2025 · strength 1.05
  3. Quanli Han · 4 shared papers, 2017–2025 · strength 0.69
  4. Mancang Gu · 4 shared papers, 2018–2024 · strength 0.56
  5. Liangchao Zhao · 2 shared papers, 2023–2025 · strength 0.47
  6. Kaidi Chen · 2 shared papers, 2023–2024 · strength 0.42
  7. Shasha Guan · 2 shared papers, 2022–2023 · strength 0.32
  8. Chen Yang · 2 shared papers, 2017 · strength 0.18
  9. Yingbin Liu · 1 shared paper, 2023 · strength 0.18
  10. Mengyin Wu · 1 shared paper, 2023 · strength 0.18
  11. Chen Fu · 1 shared paper, 2023 · strength 0.18
  12. Jie Li · 1 shared paper, 2022 · strength 0.15
  13. Di Feng · 1 shared paper, 2019 · strength 0.09
  14. Li Liu · 1 shared paper, 2019 · strength 0.09
  15. Yifan Qian · 1 shared paper, 2019 · strength 0.09
  16. Guang Hai Dai · 1 shared paper, 2017 · strength 0.09
  17. Jie Li · 1 shared paper, 2017 · strength 0.07
  18. Rong Liu · 1 shared paper, 2017 · strength 0.07
  19. Ana Babić · 1 shared paper, 2018 · strength 0.05
  20. David C. Linehan · 1 shared paper, 2018 · strength 0.05
  21. Albert C. Koong · 1 shared paper, 2018 · strength 0.05
  22. Chen Yuan · 1 shared paper, 2018 · strength 0.05
  23. Richard Francis Dunne · 1 shared paper, 2018 · strength 0.05
  24. Andrea J. Bullock · 1 shared paper, 2018 · strength 0.05
  25. Thomas E. Clancy · 1 shared paper, 2018 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.